NovaBridge Biosciences (NBP) Preferred Stock Liabilities (2018 - 2020)

NovaBridge Biosciences (NBP) has reported Preferred Stock Liabilities for 3 consecutive years, with $687.5 million the latest figure, recorded in Q4 2020.

• In Q4 2020, Preferred Stock Liabilities rose 56.1% year-over-year to $687.5 million; the TTM figure through Dec 2020 stood at $687.5 million (up 56.1% YoY), while the FY2020 annual figure was $687.5 million, up 2527.99% from the prior year.
• Preferred Stock Liabilities steadied at $687.5 million in Q4 2020 per NBP's latest filing, from $687.5 million in the prior quarter.
• Across five years, Preferred Stock Liabilities topped out at $687.5 million in Q2 2020 and bottomed at $421.6 million in Q4 2018.
• Historically, Preferred Stock Liabilities has averaged $559.3 million across 3 years, with a median of $564.0 million in 2019.
• Annual changes were most pronounced in 2019 — Preferred Stock Liabilities advanced 4.45% — and 2020, when it surged 56.1%.
• NovaBridge Biosciences' Preferred Stock Liabilities stood at $421.6 million in 2018, then gained by 4.45% to $440.4 million in 2019, then soared by 56.1% to $687.5 million in 2020.
• Business Quant data shows NBP's Preferred Stock Liabilities at $687.5 million in Q4 2020, $687.5 million in Q2 2020, and $440.4 million in Q4 2019.